Literature DB >> 23105402

Attempting to maintain normoglycemia during cardiopulmonary bypass with insulin may initiate post-operative hypoglycemia.

O P Sanjay1, P Prashanth, Deepak Ivan Tauro.   

Abstract

Cardiopulmonary bypass is known to cause alterations in insulin secretion and resistance, resulting in profound hyperglycemia. Aggressive treatment of the resulting hyperglycemia intra-operatively could result in a severe degree of post-operative hypoglycemia. We undertook this prospective non-randomized clinical study to compare the alterations in glucose homeostasis in diabetic (group A, n=50) and non-diabetic (Group B, n=50) patients undergoing moderate hypothermic (30°C) cardiopulmonary bypass for coronary artery bypass grafting (CABG). All patients had a fasting blood sugar level done on the morning of surgery. Blood sugars were monitored intra-operatively and post-operatively at fixed time intervals. Intra-operative hyperglycemia was treated aggressively by a continuous, infusion of injecting plain insulin. Both the groups experienced similar significant increase in blood glucose levels during bypass ('p'=0.00003). However, the mean blood glucose level upon arrival in the intensive care unit was significantly decreased in group B compared to group A (p=0.0002). 60% of group B and 10% of group A patients required treatment for post-operative hypoglycemia (blood glucose level <60mg/dl). This clinical study reveals that attempting to maintain normoglycemia in this setting with Insulin may initiate post-operative hypoglycemia.

Entities:  

Keywords:  Insulin; blood glucose levels; cardiopulmonary bypass

Year:  2003        PMID: 23105402      PMCID: PMC3453891          DOI: 10.1007/BF02867377

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  16 in total

1.  Elective deep hypothermia with total circulatory arrest: changes in plasma creatine kinase BB, blood glucose, and clinical variables.

Authors:  R Ekroth; R J Thompson; C Lincoln; M Scallan; R Rossi; V Tsang
Journal:  J Thorac Cardiovasc Surg       Date:  1989-01       Impact factor: 5.209

2.  Inhibition of insulin release in infants undergoing deep hypothermic cardiovascular surgery.

Authors:  D Baum; D H Dillard; D Porte
Journal:  N Engl J Med       Date:  1968-12-12       Impact factor: 91.245

3.  Myocardial metabolism in open-heart surgery. Correlation with insulin response.

Authors:  E A Moffitt; J W Rosevear; G D Molnar; D C McGoon
Journal:  J Thorac Cardiovasc Surg       Date:  1970-05       Impact factor: 5.209

4.  Hypothermia and insulin secretion.

Authors:  D L Curry; K P Curry
Journal:  Endocrinology       Date:  1970-10       Impact factor: 4.736

5.  Benefits of a glucose-containing priming solution for cardiopulmonary bypass.

Authors:  S Metz; A S Keats
Journal:  Anesth Analg       Date:  1991-04       Impact factor: 5.108

6.  The effect of temperature management during cardiopulmonary bypass on neurologic and neuropsychologic outcomes in patients undergoing coronary revascularization.

Authors:  C T Mora; M B Henson; W S Weintraub; J M Murkin; T D Martin; J M Craver; J P Gott; R A Guyton
Journal:  J Thorac Cardiovasc Surg       Date:  1996-08       Impact factor: 5.209

7.  Glucose-insulin interactions during cardiopulmonary bypass. Hypothermia versus normothermia.

Authors:  F R Kuntschen; P M Galletti; C Hahn
Journal:  J Thorac Cardiovasc Surg       Date:  1986-03       Impact factor: 5.209

8.  Hyperglycemia during hypothermic canine cardiopulmonary bypass increases cerebral lactate.

Authors:  A E Feerick; W E Johnston; L W Jenkins; C Y Lin; J H Mackay; D S Prough
Journal:  Anesthesiology       Date:  1995-02       Impact factor: 7.892

9.  Management of diabetes during open heart surgery.

Authors:  G V Gill; I H Sherif; K G Alberti
Journal:  Br J Surg       Date:  1981-03       Impact factor: 6.939

10.  Alterations of insulin and glucose metabolism during cardiopulmonary bypass under normothermia.

Authors:  F R Kuntschen; P M Galletti; C Hahn; J J Arnulf; C Isetta; V Dor
Journal:  J Thorac Cardiovasc Surg       Date:  1985-01       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.